PDCD1 and colorectal carcinoma: As expected, we observed resistance to anti‐PD1 treatment in CRC murine models constructed with the CT26 cell line, with no differences in the volume and weight of tumors between the anti‐PD1 mAb‐treated and control groups (Figure 5c–e, P > 0.05 for all).